The publisher’s accessible subscription preview identifies the research topic and states that the underlying data are available through the National Cancer Institute’s Health Information National Trends Survey. It does not expose the study’s methods, sample size, numerical results or statistical estimates. The direction and size of any age-related difference cannot be verified from that preview.

The screening guideline cited in the article supplies relevant background, independently of the unavailable study results. In its 2021 recommendation, the US Preventive Services Task Force expanded average-risk screening to begin at age 45, compared with age 50 in its previous recommendation. This was a five-year change, not a ten-year change.

That guideline history does not itself show how often clinicians discuss screening with different age groups. Nor does it establish why any communication difference might occur. Claims about clinician training, appointment pressures, electronic reminders or patient preferences would require evidence beyond the bibliographic information available here.

This notice consequently does not report a confirmed communication deficit or recommend changes in care on the basis of this study. Its findings should be assessed from the full research report linked below. The guideline background can be checked in the USPSTF recommendation statement.

Editorial correction: An earlier version described the 50-to-45 screening-age change as ten years and presented unverified study outcomes as established findings. The interval is five years. Unsupported outcome and causal claims have been removed.

Subject of Research: Health Communication

Article Title: Age-Related Differences in Clinician Communication About Colorectal Cancer Screening in the USA

Article References: Baeker Bispo, J., Bandi, P., Jemal, A., & Islami, F. (2026). Age-Related Differences in Clinician Communication About Colorectal Cancer Screening in the USA. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10854-0

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10854-0

Keywords: colorectal cancer, cancer screening, health communication, preventive medicine, clinical guidelines, public health, Age-Related, Differences, Clinician, Communication, Colorectal, Cancer

The study, led by Fatema Habbash of Arabian Gulf University and colleagues, used multistage and systematic sampling to recruit participants and conducted face-to-face interviews with a structured questionnaire. Among the 302 women surveyed, 181, or 59.9%, had undergone mammography at least once. But only 59, or 19.6%, had been screened within the recommended interval. That distinction matters enormously. A single mammogram can detect an existing tumour, but regular screening at fixed intervals is what allows radiologists to compare images over time and identify subtle changes that signal early malignancy. The low regular-screening rate suggests that many women view mammography as a one-time event rather than an ongoing preventive habit.

The barriers the researchers identified are striking in their ordinariness. The most common reason for not screening, cited by 67.9% of women, was simply believing mammography was unnecessary. Close behind, at 64.4%, was the absence of a physician recommendation. Insufficient information accounted for 42.4% of non-uptake. Fear of pain and fear of a cancer diagnosis each affected 30.9% of women, while fear of treatment or mastectomy affected 27.6%. Being asymptomatic was cited by 23.4%, embarrassment by 23.0%, concerns about radiation by 15.6%, and lack of time by 10.0%. Taken together, these numbers paint a picture of a population that largely does not see itself as at risk and has not been told otherwise by the medical professionals it trusts.

That last point deserves particular attention. The belief that mammography is unnecessary unless symptoms appear is a well-documented misconception in many populations, and it is especially consequential because early breast cancer is frequently asymptomatic. The whole purpose of screening is to detect disease before it announces itself. When nearly a quarter of women cite being asymptomatic as a reason not to screen, it signals a fundamental misunderstanding of what screening is for. Similarly, the finding that two-thirds of women lacked a physician recommendation highlights the decisive role that primary care providers play in translating public health guidelines into individual action.

When the researchers analysed which factors were actually associated with screening uptake, the results were unambiguous. Screening was significantly linked to age, family history of breast cancer, previous breast-related problems, and receiving a screening invitation from a healthcare provider. In multivariable analysis, which adjusts for the influence of other variables, receiving a formal screening invitation within the previous two years was strongly associated with higher uptake, with an adjusted odds ratio of 5.23 and a 95% confidence interval of 2.55 to 10.72. In practical terms, women who received a formal invitation were more than five times as likely to have been screened as those who did not. That is one of the strongest effects a public health intervention can produce, and it points to a remarkably simple lever for change.

The other significant predictors reinforce the clinical logic of existing screening programmes. Women aged 50 and above were more likely to undergo screening, consistent with the fact that breast cancer risk rises with age and that most international guidelines prioritise this group. Women with a family history of breast cancer were also more likely to screen, reflecting heightened perceived susceptibility. And those with previous breast-related problems were more likely to have had a mammogram, likely because such problems prompt clinical follow-up. What emerges is a pattern in which women who already perceive themselves as at risk, or who have been personally prompted by the health system, take action, while everyone else falls through the cracks.

The implications for Bahrain and the wider Gulf region are significant. The Gulf Cooperation Council countries share cultural, demographic, and healthcare-system characteristics, and the barriers identified here—misconceptions about necessity, fear of diagnosis, embarrassment, and reliance on physician prompting—are likely to resonate across the region. The study’s authors argue that culturally tailored health education, systematic screening invitations, and proactive physician recommendations may improve participation. The strength of the invitation effect suggests that a structured invitation system, in which every eligible woman receives a formal prompt at recommended intervals, could dramatically raise regular screening rates without requiring new technology or infrastructure.

The researchers also point toward the future of screening outreach. They call for future research to assess technology- and AI-supported outreach strategies, especially for younger, asymptomatic, and under-screened women. The logic is compelling: the women least likely to screen are those who feel well and see no reason to visit a clinic, and reaching them may require digital reminders, mobile health applications, or AI-driven risk stratification that identifies who needs prompting most. In a country with high smartphone penetration and a well-developed primary healthcare network, the technical foundations for such outreach already exist.

What makes this study particularly valuable is its methodological rigour. By randomly selecting participants across all four governorates using multistage and systematic sampling, the researchers produced a sample that reflects the broader population of Bahraini women in the target age range. The face-to-face interview approach minimised literacy barriers and ensured consistent data collection. The multivariable analysis distinguished between factors that merely correlate with screening and those that independently drive it. The finding that a formal invitation independently predicts uptake, even after adjusting for age, family history, and breast-related problems, gives policymakers a clear, evidence-based target.

For a condition that is the most common cancer among women worldwide, the gap between what screening can achieve and what regular screening rates actually are remains one of public health’s most stubborn challenges. This study shows that in Bahrain, the solution may not lie in convincing women one by one, but in building a system that reaches out to them automatically. A formal invitation, delivered at the right interval, backed by culturally attuned education and proactive primary care physicians, could transform mammography from an occasional event into a routine preventive habit. The evidence suggests that the simplest intervention—asking women to come in for screening—may be the most powerful one available.

Subject of Research: Public Health

Article Title: Determinants and barriers to mammography screening uptake among Bahraini women: a cross-sectional study in primary healthcare settings

Article References: Habbash, F., AlMohri, M., Waleed, A., Hamdan, H., Salman, K., Obaid, S., Abdulla, Z., Almarabheh, A., & Salah, A. B. (2026). Determinants and barriers to mammography screening uptake among Bahraini women: a cross-sectional study in primary healthcare settings. BMC Public Health. https://doi.org/10.1186/s12889-026-29859-9

Image Credits: AI Generated

DOI: 10.1186/s12889-026-29859-9

Keywords: mammography, breast cancer screening, Bahrain, public health, preventive medicine, primary healthcare, cancer epidemiology, Determinants, barriers, screening, uptake, Bahraini

Researchers from the Huzhou Center for Disease Control and Prevention, working alongside colleagues from the Zhejiang Provincial Center for Disease Control and Prevention and several district-level health agencies, conducted a cross-sectional survey among older adults aged 60 and above who had screened positive for latent tuberculosis infection, or LTBI. The study, published in Frontiers in Cellular and Infection Microbiology, set out to answer a deceptively simple question: among older people who carry the dormant bacterium and are medically eligible for preventive treatment, who actually agrees to take it?

Latent tuberculosis infection is a peculiar biological state. The bacterium, Mycobacterium tuberculosis, sits quietly inside the body, held in check by the immune system, causing no symptoms and no active disease. But it can reactivate at any time, particularly when the immune system weakens with age. Older adults are especially vulnerable to this reactivation. Age-related immune senescence—the gradual deterioration of immune function that comes with growing older—combined with a high burden of chronic diseases, delayed healthcare-seeking due to atypical symptoms, and the sheer passage of time since the original infection, makes the elderly population a priority target for tuberculosis prevention. In China, the reported incidence of active pulmonary tuberculosis among people aged 65 and above is substantially higher than the national average, and the prevalence increases with age.

The World Health Organization’s End TB Strategy explicitly identifies tuberculosis preventive treatment, or TPT, for high-risk populations with LTBI as a key intervention to reduce tuberculosis incidence and interrupt transmission. Short-course chemoprophylaxis regimens, such as three months of rifapentine combined with isoniazid, have favorable safety and adherence profiles, providing a feasible technical foundation for scale-up in older populations. But translating effective treatment protocols from theoretically viable to practically implemented faces substantial real-world barriers. Prior studies have largely focused on the efficacy, safety, and cost-effectiveness of TPT regimens, or broadly examined adherence-related factors in the general population. When narrowed to the specific subgroup of adults aged 60 and above, the initial decision-making process regarding whether to accept TPT remains a relatively neglected blind spot in the literature.

The Huzhou study recruited 620 older adults with LTBI through two channels: community-based health examinations for older adults and screening of close contacts of active tuberculosis patients. All participants were clinically evaluated as meeting the medical indications for TPT according to Chinese guidelines, with clear consciousness and basic communication ability. Individuals with confirmed active pulmonary tuberculosis, contraindications to TPT such as severe hepatic dysfunction or allergy to treatment medications, and severe mental illness or cognitive impairment were excluded. The study offered participants two types of preventive treatment: chemoprophylaxis regimens and Mycobacterium vaccae immunotherapy. Most participants chose the short-course chemoprophylaxis regimen due to its convenient dosing, while immunotherapy provided an alternative for those unsuitable for or reluctant to undergo chemotherapy.

The results were striking. Of the 620 participants enrolled, 430—69.35 percent—accepted TPT. Among the participants, 354 were male, 192 were aged over 70 years, 593 were married, 499 resided in rural areas, 577 had an education level of junior high school or below, 135 smoked daily or occasionally, and 152 consumed alcohol occasionally or at least twice weekly. The acceptance rate was relatively high, indicating a reasonable implementation foundation for preventive intervention. Nevertheless, approximately 30 percent of the eligible population did not initiate treatment, suggesting that intervention strategies require further optimization.

To identify the factors driving treatment decisions, the researchers performed univariate and multivariate Logistic regression analyses. Variables with P less than 0.2 in the univariate analysis were entered into a multivariate unconditional Logistic regression model using a forward stepwise procedure. The analysis revealed three independent factors associated with TPT acceptance. Participants from households with three or fewer persons had an 88 percent increase in the odds of accepting TPT, with an adjusted odds ratio of 1.88 and a 95 percent confidence interval of 1.15 to 3.07. Those with an annual household income of 150,000 Chinese yuan or less had a 124 percent increase in the odds, with an adjusted odds ratio of 2.24 and a 95 percent confidence interval of 1.33 to 3.77. And those with a history of underlying diseases had an 86 percent increase in the odds, with an adjusted odds ratio of 1.86 and a 95 percent confidence interval of 1.16 to 2.99.

The finding that lower household income was associated with higher TPT acceptance appears to contradict the conventional assumption that lower socioeconomic status is generally associated with unfavorable health behaviors. But the researchers propose three plausible, mutually non-exclusive pathways that may explain this observation in the context of Huzhou. First, the financial barriers that typically link poverty to poor treatment uptake were largely absent in this setting: under national guidelines and Huzhou’s tuberculosis control program, TPT—including medications, baseline examinations, and follow-up monitoring—was delivered free of charge through the local CDC system at primary healthcare facilities. Second, the opportunity costs of accepting TPT likely differed by income. The sample was predominantly rural older adults, most of whom had exited the labor market, whereas higher-income participants were more likely to remain economically active; for these individuals, the repeated follow-up visits and laboratory monitoring required by TPT may have imposed substantial time and opportunity costs, thereby discouraging acceptance. Third, lower-income participants may have perceived greater vulnerability to disease and therefore regarded the freely offered preventive intervention as a worthwhile health investment.

The association between smaller household size and TPT acceptance suggests that family structure plays a pivotal role in health-related decision-making among older adults. Smaller households may facilitate more direct communication and concentrated caregiving responsibilities, with family members’ attention to and encouragement of the older adult’s health being more effective, thereby promoting TPT acceptance. Meanwhile, the finding that older adults with underlying diseases were more likely to accept TPT strongly supports the applicability of the perceived susceptibility construct of the health belief model in older populations. Those with comorbidities such as diabetes and chronic respiratory diseases may more acutely perceive their health vulnerability and hold stronger perceptions of tuberculosis as an infectious threat, thereby showing greater propensity to adopt preventive measures.

Several variables that were significant in the univariate analysis lost significance in the multivariate model, highlighting the complex interplay among influencing factors. Age of 70 years or younger, close contact status, alcohol consumption, and higher body mass index were associated with TPT acceptance in the univariate analysis, but their independent effects were attenuated after controlling for household, economic, and health-related factors. This suggests that the influence of these variables on treatment decisions may be mediated through, or contingent upon, deeper socioeconomic and health-perception factors. The researchers caution that the cross-sectional design precludes determination of temporal ordering, and reverse causation cannot be excluded. Future longitudinal studies incorporating data on time availability, occupational status, and out-of-pocket costs are needed to disentangle these competing explanations. The study also relied on structured questionnaires without qualitative data on the deeper motivations, concerns, and family interaction processes underlying older adults’ treatment decisions, and was conducted in Huzhou, an economically developed city in eastern China with a well-established primary tuberculosis control network, so the findings may not be directly generalizable to less developed regions.

Despite these limitations, the study provides an evidence base for developing precision-targeted intervention strategies. The researchers suggest that future efforts should transcend simple information dissemination models and instead adopt integrated approaches: for individuals from larger households, incorporate family mobilization components into health education; for those with better economic conditions and without underlying diseases, strengthen personal risk perception; and leverage the intrinsic motivation of those with comorbidities, transforming them into active advocates for community-based prevention. Through such precision-targeted, multi-level interventions, TPT coverage among this critical older population may be further improved, thereby solidifying the foundation for achieving the goal of ending tuberculosis.

Subject of Research: Infectious Diseases

Article Title: Factors associated with acceptance of preventive treatment among older adults with latent tuberculosis infection in Huzhou, Zhejiang province: a cross-sectional study

Article References: Yang, Z., Zu, Z., Sun, X., Chen, X., Wang, W., Zheng, P., Wen, D., Ren, F., Ding, Z., Gan, M., Wang, H., Zhang, S., Kong, Y., Jiang, G., Fan, J., Qin, J., You, J., Jin, M., Chen, B., … Shen, J. (2026). Factors associated with acceptance of preventive treatment among older adults with latent tuberculosis infection in Huzhou, Zhejiang province: a cross-sectional study. Frontiers in Cellular and Infection Microbiology, 16, Article 1967858. https://doi.org/10.3389/fcimb.2026.1967858

Image Credits: AI Generated

DOI: 10.3389/fcimb.2026.1967858

Keywords: tuberculosis, latent tuberculosis infection, tuberculosis preventive treatment, older adults, public health, China, epidemiology, preventive medicine, Factors, associated, acceptance, preventive

The study exploited a uniquely rich data resource: the National Health Insurance Service Health Screening Cohort, known as NHIS-HEALS. Korea operates a universal single-payer system that covered approximately 97 percent of the population as early as 1989, and enrollment in the system mandates biennial health screenings that record anthropometry, laboratory markers, and self-reported behaviors. Because the cohort is built from administrative claims rather than surveys, it avoids the recall bias and measurement error that plague self-reported data. The researchers selected a 10 percent random sample of adults aged 40 to 79 who underwent national health screening in 2002 and 2003, then applied strict exclusions to remove former smokers, people with baseline chronic diseases such as hypertension, diabetes, stroke, or cancer, and anyone with missing behavioral data across the trajectory estimation waves.

To capture the joint evolution of the four behaviors, the team used group-based multi-trajectory modeling, a statistical technique designed to identify qualitatively distinct subgroups within a population rather than describing average change around a single mean. Smoking was categorized by cigarettes per day, alcohol intake by grams per day, physical activity by weekly frequency of moderate-to-vigorous exercise, and BMI by Korean obesity guidelines. Model fit was assessed using the Akaike Information Criterion, the Bayesian Information Criterion, entropy, and average posterior probability, and a six-group solution emerged as optimal for both males and females. This approach matters because single-behavior analyses fail to capture the clustering and interactive effects of co-occurring risk behaviors, which is precisely where much of the health burden hides.

The six trajectories told a striking story. Among the 95,226 men, roughly 30 percent maintained a stable healthy pattern of non-smoking, low alcohol intake, increasing physical activity, and normal BMI, while 28 percent showed progressive improvement across all behaviors. Two moderate-risk groups, together comprising about 40 percent, sustained smoking, moderate drinking, and low physical activity, differing mainly in whether they carried overweight or normal BMI. Two small severe-risk groups, each around 1 percent, combined light smoking, minimal activity, and either persistent underweight or severe obesity. Among the 72,117 women, the picture differed: nearly 35 percent were stably healthy, and the moderate-risk groups were defined primarily by overweight or obese BMI rather than by smoking or drinking, since most women were nonsmokers and nondrinkers.

The associations with healthcare outcomes were assessed using generalized estimating equations stratified by sex, with adjustments for age, region, insurance type, income, disability status, and the Charlson Comorbidity Index. For inpatient expenditure and length of stay, which showed substantial zero-inflation with roughly 80 percent of observations at zero, the researchers applied a two-part modeling framework: a logistic model for the probability of any hospitalization, and a gamma model with a log link for the magnitude among those hospitalized. Outpatient expenditure and visit counts, with fewer than 0.3 percent zero observations, required only single-part models. An autoregressive order 1 correlation structure was selected because healthcare spending in a given year correlates most strongly with the immediately preceding year.

The results were dramatic and sex-specific. Among men, the higher severe-risk trajectory was associated with outpatient expenditure 12.5 percent higher and inpatient expenditure 60.6 percent higher than the stable healthy group, along with 4 percent more outpatient visits and 22 percent longer hospital stays. But the most intriguing finding concerned the higher moderate-risk group: these men, despite normal BMI, younger age, and lower comorbidity, showed 3.7 percent fewer outpatient visits yet 24.4 percent longer hospital stays. This pattern echoes what epidemiologists call the lean paradox, in which normal-weight individuals with poor smoking, drinking, and activity profiles visit outpatient care less but hospitalize more, possibly because they engage in less preventive care and present with more advanced disease when they finally do.

Among women, the higher severe-risk trajectory, affecting less than 1 percent of the cohort, was linked to outpatient expenditure 14.8 percent higher, inpatient expenditure 74.7 percent higher, 6 percent more outpatient visits, and 45.4 percent longer hospital stays. Smoking lowers estrogen levels, and women show greater physiological susceptibility to alcohol-related harm, which may partly explain why adverse behaviors carry such heavy costs in this group. More paradoxically, the female decreasing-risk trajectory, representing women who improved their behaviors over time, showed higher expenditure and utilization than the stable healthy reference group, unlike their male counterparts. The authors propose several mechanisms: health-conscious women may simultaneously adopt broader health-promoting behaviors that elevate short-term utilization, the benefits of behavioral improvement may require a longer time horizon than the 11-year follow-up to manifest as cost savings, and estrogen-mediated protection in younger women may attenuate observable benefits while its withdrawal after menopause amplifies residual damage from prior unhealthy behaviors.

Age-stratified analyses added another layer of nuance. Among men under 65, severe-risk trajectories showed the strongest associations with inpatient expenditure and length of stay, likely reflecting early disease onset and intensive treatment needs. Among men 65 and older, moderate-risk trajectories dominated, consistent with the cumulative damage of persistent smoking and heavy drinking in later life worsening comorbidities and hospitalization rates. Among women, the higher severe-risk trajectory was strongly associated with higher inpatient expenditure and longer stays in both age groups, with coefficients of 0.624 in the younger group and 0.477 in the older group. These patterns suggest that the behavioral drivers of healthcare demand shift across the life course, and that prevention strategies must be tailored accordingly.

The stakes are enormous. Non-communicable diseases account for approximately 71 trillion Korean won annually in Korea, nearly 85 percent of total healthcare costs, and Korean healthcare expenditure has been growing at the fastest rate among OECD countries. The socioeconomic losses attributable to smoking, high-risk drinking, physical inactivity, and obesity reached approximately 42 trillion won in 2019. Out-of-pocket spending remains above the OECD average, and the long-term financial sustainability of the health system is under pressure. The authors argue that community-level health policies in Korea have focused primarily on interventions after disease onset, and that adopting prevention-oriented approaches, as demonstrated in Japan where community-based health promotion programs reduced healthcare expenditure, could enhance the effectiveness of preventive policy.

The study has limitations worth noting. Substantial sample exclusions, including 258,970 individuals removed for missing data or death and 83,918 for baseline chronic conditions, likely produced a healthier-than-average analytic sample, and excluded participants differed significantly in age, income, and disability status. Unmeasured confounders such as diet, sleep, education, occupation, and health literacy may have influenced both behaviors and utilization. Physical activity was measured only by weekly frequency, without duration or intensity, and pharmacy costs were excluded because Korean claims data do not disaggregate pharmaceutical expenditure by care setting, which may underestimate the total financial burden of unhealthy trajectories. Nevertheless, the core message stands: healthcare demand is shaped by long-term, multidimensional behavioral patterns rather than by single risk factors, and preventive interventions should address not only high-risk groups but also individuals with normal BMI who continue to smoke, drink, or remain inactive. Strengthening community-based prevention may be the key to reducing the healthcare burden and sustaining Korea’s health system for decades to come.

Subject of Research: Health

Article Title: Joint trajectories of health behaviors and their associations with healthcare utilization and expenditure

Article References: Yang, J. M., Kim, J. M., Jang, T. S., & Hwang, J. (2026). Joint trajectories of health behaviors and their associations with healthcare utilization and expenditure. International Journal of Public Health, 71, Article 1609686. https://doi.org/10.3389/ijph.2026.1609686

Image Credits: AI Generated

DOI: 10.3389/ijph.2026.1609686

Keywords: health behavior, healthcare expenditure, South Korea, NHIS-HEALS, trajectory modeling, public health, preventive medicine, Joint, trajectories, health, behaviors, associations

The research team, based at Steno Diabetes Center Copenhagen, interviewed 28 adults aged 17 to 42 who were participating in DiaUnion, a Danish-Swedish screening initiative that targets first-degree relatives of people with type 1 diabetes. Denmark is currently the only country screening first-degree relatives rather than the general population, combining islet autoantibody testing with genetic screening and offering home-based blood sampling alongside digital follow-up. Participants were recruited at different stages of the process: fourteen were still awaiting results, seven had received negative results, and seven had tested positive for one or more autoantibodies. Semi-structured interviews, conducted by telephone, home visit, or clinic meeting between May and August 2025, were analyzed using reflexive thematic analysis.

The biological backdrop matters for understanding what participants were interpreting. Type 1 diabetes is an autoimmune disease in which the immune system progressively destroys the insulin-producing beta cells in the pancreatic islets of Langerhans, leading to absolute insulin deficiency and chronic hyperglycemia. The disease typically progresses silently for years but can be detected in its preclinical stages through blood tests for multiple islet autoantibodies and early signs of dysglycemia. One autoantibody carries roughly a 15 percent risk of developing the disease within ten years; two autoantibodies signal an almost 85 percent risk within fifteen years, and persistent presence of two or more is associated with nearly certain eventual onset. First-degree relatives carry a lifetime risk of about 5 to 10 percent, compared with roughly 0.3 percent in the general population, and adults account for more than half of all new diagnoses—yet most screening research has historically focused on children.

The first major theme the researchers identified concerns how family narratives shape risk perception. Participants whose parents had openly discussed and managed their diabetes during childhood tended to describe the condition as a familiar, integrated part of everyday life rather than a threat. One participant whose mother uses a pump sensor recalled measuring her own blood sugar as a kind of fun childhood activity and described feeling calm about whatever the screening outcome might be. But the researchers noted that this openness was selective: participants described positive experiences while rarely mentioning severe complications, suggesting that some parents practiced a form of protective disclosure, shielding children from the harder realities of the disease. The result is an inherited narrative in which diabetes appears controllable and relatively uncomplicated—a narrative that may contribute to underestimating its seriousness.

The opposite pattern also emerged. Participants who grew up watching a relative struggle with poorly controlled diabetes described childhood fear and a lifelong vigilance about anything that might raise or lower their chances of developing the disease. One participant whose father experienced repeated severe hypoglycemic episodes said the illness had frightened the family and created a desperate desire to avoid anything that might cause it. Concealment added another layer: when diabetes was treated as a family taboo, participants understood it not only as a physical illness but as something associated with shame. Some parents who had difficult experiences actively encouraged their adult children to join the screening program, which the researchers interpret as an attempt to break a family narrative linking diabetes with stigma.

A striking temporal misunderstanding ran through many accounts. Participants frequently anchored their perceived vulnerability to the age at which their parent was diagnosed. One participant noted that her mother developed diabetes at 33 and, with her own 32nd birthday approaching, felt the timing was suddenly relevant to her. Many others concluded that because they had passed the age at which their parent was diagnosed, they were no longer at meaningful risk. The researchers point out that type 1 diabetes can develop at any age and that this life-window framing of genetic susceptibility is biologically inaccurate—yet it serves a protective psychological function, allowing people who feel they have moved beyond the danger period to distance themselves from vulnerability.

The second theme revealed gaps in biomedical knowledge even among people with a close family member with the disease. Several participants believed type 1 diabetes occurs largely at random while type 2 diabetes is the hereditary form, leading them to underestimate their genetic risk. Many described maintaining healthy diets and exercise routines as a way to prevent type 1 diabetes from developing, even though there is currently no evidence that lifestyle behaviors prevent its autoimmune onset. The researchers interpret this emphasis on lifestyle through the lens of the Health Belief Model: focusing on controllable behaviors transforms an unmanageable genetic risk into something that feels predictable, providing emotional comfort and a sense of agency even when perceived control does not align with actual disease mechanisms. One participant acknowledged the possibility herself, wondering aloud whether her calm derived from a kind of false sense of security.

The third theme concerned how screening results themselves were interpreted. Participants repeatedly compared type 1 diabetes favorably to conditions they considered far more severe, particularly cancer, reasoning that people they knew lived normal lives with diabetes and that doctors knew how to handle it. The researchers describe this comparative framing as cognitive reframing—a coping strategy that creates psychological distance from fear by positioning diabetes as survivable and manageable, even though it may downplay the continuous, demanding self-management the disease actually requires. Participants also described diabetes as treatable, a word choice the researchers find telling, since type 1 diabetes is a chronic condition without a cure; what exists are management strategies, not remedies. The perception that medical progress has made the disease nearly curable appears to further reduce fear.

Perhaps most paradoxical was the attitude captured in the study’s title. One participant described the screening as something nice to know rather than need to know, saying the family could live just as good a life without the information. Others forgot they had even taken the test until the result arrived, and those who tested negative reported feeling neither relief nor gratitude—simply, now I know. Participants who tested positive for a single autoantibody often dismissed the result as not serious, positioning themselves outside what they perceived as the real risk group, despite the clinical significance of autoantibody positivity and the need for structured follow-up. Negative results were sometimes treated as definitive reassurance, including reassurance about not having passed genetic risk to children, even though a negative screening result represents only a point-in-time indication rather than a permanent all-clear.

The researchers argue that this downplaying should not be read simply as a failure of knowledge transmission but as active meaning-making. For adult first-degree relatives, familial risk is not new information but a pre-existing condition of life, already managed through normalization, reframing, and perceived controllability. A positive result may feel less like disruptive news and more like confirmation of something long expected, making it psychologically easier to integrate than to reconstruct one’s self-understanding around future disease. Notably, the study’s companion findings on parents of screened children showed a different pattern: those parents engaged with screening as a tool for managing fear and preparing for their child’s possible diagnosis, whereas the adults screened for themselves relied on strategies that normalize and minimize risk.

The practical implications are significant for the growing field of early detection, which has been energized by immunomodulatory therapies such as teplizumab, approved by the European Medicines Agency in January 2026, that can delay clinical onset. The authors conclude that standardized risk communication is insufficient because individuals filter information through established personal and familial narratives. Screening programs, they argue, should adopt more individualized approaches that engage with participants’ existing frameworks of understanding, and should not assume that an absence of expressed need for support means an absence of psychological burden—concerns may simply be managed invisibly through coping strategies that keep them out of sight.

Subject of Research: Risk perception and psychosocial experiences of adult first-degree relatives participating in early detection screening for type 1 diabetes

Article Title: “This is going to be a nice-to-know, not a need-to-know”: absence of concern – a qualitative study of risk perception in early detection of type 1 diabetes

Article References: Pedersen, E. B., Flarup, P. B., Jespersen, L. N., Due-Christensen, M., Antvorskov, J. C., Pociot, F., & Grabowski, D. (2026). “This is going to be a nice-to-know, not a need-to-know”: absence of concern – a qualitative study of risk perception in early detection of type 1 diabetes. Frontiers in Clinical Diabetes and Healthcare, 7, Article 1925120. https://doi.org/10.3389/fcdhc.2026.1925120

Image Credits: AI Generated

DOI: 10.3389/fcdhc.2026.1925120

Keywords: type 1 diabetes, early detection, autoantibody screening, risk perception, first-degree relatives, qualitative research, DiaUnion, psychosocial, health communication, coping strategies, preventive medicine, Denmark

The research, led by Adoma Manful of Vanderbilt University Medical Center together with senior authors Jennifer Richmond of Wake Forest University School of Medicine and Meng-Yun Lin, also of Wake Forest, set out to quantify how the guideline change reshapes the pool of people who qualify for annual screening. The team used data from the National Health Interview Survey, a large, publicly available household survey administered by the National Center for Health Statistics at the Centers for Disease Control and Prevention. Because the survey is designed to represent the civilian, noninstitutionalized population of the United States, it allows researchers to translate eligibility criteria written on paper into estimates of how many real people, and which kinds of people, would now be directed toward screening.

To understand why the change matters, it helps to trace the short history of lung cancer screening policy. The landmark National Lung Screening Trial, published in the New England Journal of Medicine in 2011, demonstrated that annual LDCT screening reduced lung cancer mortality by 20 percent compared with chest radiography among people at high risk. That evidence gave rise to the first national screening recommendations, which used a combination of age, smoking intensity measured in pack-years, and years since quitting to define eligibility. The US Preventive Services Task Force later broadened its criteria in 2021, lowering the starting age to 50 and the smoking threshold to 20 pack-years, but it retained a cutoff that excluded anyone who had quit smoking more than 15 years earlier.

The American Cancer Society’s 2023 guideline update broke with that tradition. Drawing on modeling analyses, including work by Landy and colleagues showing that absolute lung cancer risk continues to rise among former smokers with more than 15 quit-years, the Society removed the years-since-quitting restriction entirely. Under the updated recommendation, adults aged 50 to 80 who currently smoke or formerly smoked and have at least a 20 pack-year smoking history are eligible for annual LDCT screening, regardless of how long ago they stopped. The rationale was straightforward: a person’s cumulative exposure does not vanish the moment they extinguish their last cigarette, and former smokers who quit long ago may still carry substantial residual risk.

The new analysis asked a deceptively simple question about that expanded eligibility: among the people swept into the screening pool by the removal of the quit-years limit, what is their predicted risk of lung cancer? This question matters because screening is not free of downsides. LDCT scans detect a large number of incidental findings, including nodules that turn out to be benign, and every follow-up scan, biopsy, or surgery carries its own burden of anxiety, cost, and occasional harm. Screening programs work best when they concentrate on people whose underlying probability of disease is high enough that the expected benefit of early detection outweighs these risks. If the expanded criteria bring in large numbers of people at low predicted risk, the efficiency of the entire enterprise could be diluted.

Using the National Health Interview Survey data, the investigators classified respondents according to the old and new eligibility criteria and estimated the predicted lung cancer risk of each group. The study, which was funded by the National Institute on Minority Health and Health Disparities under award R21MD020158, was reviewed and deemed exempt by the Wake Forest University School of Medicine Institutional Review Board, with all survey participants having provided informed consent. The authors report no conflicts of interest, and the funding agencies had no role in the design, analysis, or decision to publish the findings.

The technical heart of the study lies in how smoking exposure is translated into risk. Pack-years, the standard metric, multiply the number of packs smoked per day by the number of years of smoking, yielding a cumulative dose measure. Risk prediction models developed for screening selection, including the widely used criteria from Tammemägi and colleagues published in 2013, incorporate pack-years alongside age, sex, and other characteristics to estimate an individual’s probability of developing or dying from lung cancer within a defined period. By applying such risk stratification to a nationally representative sample, the researchers could compare the risk profiles of people eligible under the previous rules with those eligible only under the expanded 2023 criteria, providing an evidence-based picture of who the guideline change actually adds.

The findings carry practical weight for clinicians and health systems preparing to implement the expanded guidelines. Primary care practices, which serve as the main gateway to screening, now face a larger eligible population and must decide how to prioritize outreach, shared decision-making visits, and imaging capacity. The study’s risk-based framing offers a way to think about that challenge: eligibility rules define the outer boundary of who may benefit, but predicted risk within the eligible pool varies considerably, and understanding that variation can help clinicians communicate more honestly with patients about the likely balance of benefits and harms. It also informs the ongoing debate about whether screening selection should move away from simple smoking-history thresholds toward more refined, multivariable risk models.

There is an equity dimension as well. Lung cancer screening uptake in the United States has remained strikingly low, with only a small fraction of eligible adults receiving annual scans, and disparities in access and completion persist across racial, geographic, and socioeconomic lines. The National Institute on Minority Health and Health Disparities funding of this work reflects growing recognition that guideline expansions only save lives if the people they cover actually get screened. The authors, who include thoracic surgeon Brian Mitzman of the University of Utah Health and Huntsman Cancer Institute, health economist Richard Nelson of the VA Salt Lake City Healthcare System, and pharmacoepidemiologist Nathorn Chaiyakunapruk, bring a deliberately multidisciplinary perspective to a problem that spans oncology, implementation science, and health policy.

The broader lesson of the study is that screening guidelines are living instruments that must be recalibrated as evidence accumulates. The removal of the quit-years limit was a principled correction grounded in the biology of tobacco-related carcinogenesis, where risk declines slowly, if at all, after cessation. By measuring the predicted risk of the newly eligible population in a nationally representative frame, this research gives policymakers and clinicians a clearer view of the trade-offs embedded in the expanded criteria. As screening programs scale up to meet the larger eligible population, the findings underscore a central tenet of modern cancer prevention: the goal is not simply to scan more people, but to scan the right people, at the right time, with a clear-eyed understanding of who stands to benefit most.

Subject of Research: Predicted lung cancer risk among adults newly eligible for low-dose CT screening under the expanded 2023 American Cancer Society guidelines

Article Title: Expanded American Cancer Society Lung Cancer Screening Eligibility and Predicted Risk

Article References: Manful, A., Aldrich, M. C., Mitzman, B., Chaiyakunapruk, N., Nelson, R. E., Richmond, J., & Lin, M.-Y. (2026). Expanded American Cancer Society Lung Cancer Screening Eligibility and Predicted Risk. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10907-4

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10907-4

Keywords: lung cancer, cancer screening, low-dose CT, American Cancer Society, smoking, pack-years, risk prediction, National Health Interview Survey, screening guidelines, health disparities, preventive medicine, public health

The scale of the analysis is what sets the study apart. The research team, led by Dr. Glen Pridham and Yoav Hayut from Alon’s lab in Weizmann’s Molecular Cell Biology Department, drew on two enormous datasets: results from the US National Health and Nutrition Examination Survey, collected over more than two decades, and medical records spanning roughly 20 years from Clalit, Israel’s largest health insurer. Datasets of this size are rarely brought to bear on menopause research, and the reason is simple: they usually lack the one piece of information that matters most for this kind of analysis, namely the age at which each woman had her final period.

That missing information creates a fundamental problem for anyone trying to pin down what happens at menopause itself. If women reach menopause at different ages, and a researcher aligns their medical records by calendar age, the true signal of the transition gets smeared across time. A sharp change that occurs at age 51 in one woman and age 54 in another looks, in the averaged data, like a gradual change stretched over several years. The apparent slowness of menopause, in other words, could partly be an artifact of the way the data are pooled rather than a property of the biology itself.

To cut through this blur, the Weizmann team borrowed an idea from an unexpected field: astronomy. Astronomers routinely sharpen images distorted by the optics of their telescopes by mathematically correcting for those distortions, a process known as deconvolution. The researchers developed a computational method inspired by this approach that removed the blurring introduced by differences in the age at which women reach menopause. Once that correction was applied, what emerged from the data was not a gentle slope but a distinct physiological turning point, a sudden shift in dozens of bodily measures concentrated around the time of the last menstrual period.

The breadth of the changes came as a surprise. Of the 90 types of laboratory tests examined, 52 showed abrupt changes at the transition, covering nearly all body systems. The affected measures included markers of bone health, liver function, kidney function, and cholesterol levels, alongside the expected shifts in sex hormones. This suggests that menopause is not confined to the reproductive axis but registers across the organism, with the end of ovarian hormone production rippling outward into metabolism, skeletal maintenance, and organ function in a coordinated and comparatively rapid way.

Two comparison groups in the data helped sharpen the interpretation. No such abrupt changes were observed in men of similar ages, indicating that the turning point is specific to the female transition rather than a general feature of aging in midlife. And among women receiving menopausal hormone therapy, the changes were less pronounced, a pattern consistent with the idea that the declining hormone levels themselves drive much of the body-wide shift. While the study’s design does not by itself establish hormone therapy as protective, the contrast offers a natural experiment hinting that supplementing the hormones lost at menopause may soften the physiological transition.

The timing of the underlying hormonal changes also proved more dramatic than expected. The sudden shifts at menopause were preceded by accelerating changes in sex hormone levels that began more than a decade before the final period, several years earlier than previous research had suggested. In practical terms, the body appears to enter a period of accelerating hormonal change in the mid-to-late thirties or early forties for many women, long before the first obvious symptoms of the transition appear. The final event at menopause, on this view, is the endpoint of a long buildup rather than the beginning of the story.

Because most of the abrupt changes identified in the study are associated with increased disease risk, the findings carry a clear message for preventive medicine. Bone loss, adverse changes in cholesterol, and declining kidney and liver measures are all modifiable risk factors, and interventions such as exercise and dietary improvement are most effective when they start early. Our study extends the window for potential preventive care to almost a decade before menopause, Alon says. That reframing turns the decade before the last period from a quiet prelude into a critical window in which women and their physicians can act on measurable, trackable changes in blood tests.

The methodological contribution may prove as consequential as the biological one. The deconvolution-style approach the team developed is not specific to menopause; it can, in principle, be applied to any large medical dataset in which a key event happens at different ages for different people, allowing researchers to recover the true sharpness of the underlying transition. More broadly, the method we developed may help study other major changes in life, such as puberty, pregnancy or the onset of disease, Alon notes. If other life transitions that look gradual in population data turn out to be sharp once the blur is removed, the study could reshape how medicine thinks about aging and disease onset more generally.

The study also involved Dr. Noa Lavi-Shoseyov and Prof. Michal Neeman of Weizmann’s Immunology and Regenerative Biology Department, Dr. Noa Hovav of the Menopause Community Center at Clalit Health Care, and Dr. Yoel Toledano of the Helen Schneider Women’s Hospital at Rabin Medical Center, with Dr. Lavi-Shoseyov additionally affiliated with the IVF Unit in the Department of Obstetrics and Gynecology at Kaplan Medical Center. Taken together, the work recasts menopause as a discrete physiological event with a long and measurable runway leading up to it. For the more than one million women whose records made the discovery possible, and for the millions more approaching the transition, the practical takeaway is that the years before menopause matter far more than has been assumed, and that routine laboratory tests, viewed through the right computational lens, can reveal a turning point in time to act on it.

Subject of Research: A computational analysis of large medical datasets revealing a sudden body-wide physiological transition at menopause

Article Title: Menopause: more than a slow change, it’s a sudden shift across the body

Article References: Menopause: more than a slow change, it’s a sudden shift across the body. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: menopause, Weizmann Institute, Nature Medicine, deconvolution, sex hormones, preventive medicine, bone health, cholesterol, hormone therapy, NHANES, Clalit, biomarkers

The study, led by Tracey J. Brown and colleagues at the University of Cambridge, is a realist review of electronic signposting: the practice of sending targeted digital messages through electronic health records, patient portals, and other healthcare IT systems to point patients toward evidence-based preventive interventions. Rather than asking whether these messages work on average, the researchers set out to answer a more nuanced question — what kind of electronic signposting works, for whom, and under what circumstances. That distinction matters, because the answer determines whether health systems invest millions in messaging infrastructure that actually changes behavior or merely adds another layer of digital noise.

Realist review is a methodology designed for exactly this kind of complexity. Unlike traditional systematic reviews that pool outcomes to estimate an average effect, realist synthesis digs into the underlying causal machinery: the contexts in which an intervention operates, the mechanisms it triggers in the people receiving it, and the outcomes that follow. The team followed the RAMESES I reporting standards, searching seven major databases — Medline, EMBASE, CINAHL, Scopus, PsycINFO, ERIC, and AMED — along with grey literature, and registered their protocol prospectively on PROSPERO. Studies were included if they shed light on the context and mechanisms of electronic signposting to cancer prevention interventions for adults in any healthcare setting, and each was appraised for relevance, richness, and rigour.

From thirty included studies, twenty-six of which came from the United States, the researchers extracted fifty-seven individual context-mechanism-outcome configurations — essentially, fifty-seven documented pathways describing how a particular circumstance leads to a particular psychological or organizational response, which in turn produces a particular result. This granular mapping allowed the team to build what they call a novel programme theory: a testable, structured explanation of how electronic signposting succeeds or fails across different settings, patient populations, and technological environments.

For patients, the findings converge on two central pillars: memorability and channel fit. Messages that used wording tailored to individual patient characteristics — referencing a person’s specific health status, history, or circumstances — were far more likely to generate what the authors call buy-in, the willingness to engage with the recommended intervention. So too was delivery through a communication channel patients already use and trust, with SMS text messaging standing out as a particularly effective vehicle. A message that feels personally relevant and arrives through a familiar medium is easier to absorb, easier to remember, and easier to act on. Generic, impersonal blasts, by contrast, risk being dismissed as spam or ignored entirely, no matter how sound the clinical advice behind them.

On the provider side, the picture shifts from psychology to organizational pragmatics. Electronic signposting succeeded when it fit neatly with an organization’s existing priorities, slotted into clinical workflows without adding friction, and proved compatible with the technical systems already in place. Clinicians and health systems are not neutral conduits for digital interventions; they are gatekeepers whose cooperation depends on whether a new tool lightens their load or compounds it. A signposting system that demands workarounds, duplicates data entry, or conflicts with institutional goals will quietly wither, regardless of its evidence base.

Two subtler findings from the review carry particular weight for anyone designing digital health interventions. First, the researchers found that optimism about the technology itself — a general sense that the system is modern, capable, and worth trusting — shaped how both patients and providers responded to signposting messages. Second, and perhaps most strikingly, electronic signposting had to avoid threatening the existing relationship between patient and provider. A digital message that appears to bypass, contradict, or undermine a patient’s clinician can damage the very trust that makes preventive care work. The technology, in other words, must be positioned as an extension of the care relationship rather than a replacement for it.

The implications reach well beyond technical design. The authors argue that reducing cancer incidence and narrowing cancer disparities requires policymakers and providers to implement electronic signposting in ways that actively promote buy-in, ensure perceived usability, and nurture positive attitudes toward the technology. That framing reframes implementation as a social and psychological challenge as much as an engineering one. A perfectly coded messaging system deployed in a context of low trust, poor channel fit, and workflow disruption will fail; a simpler system aligned with patient habits and organizational priorities may succeed. For health systems in the United States, where most of the evidence currently comes from, the review offers a practical checklist for deployment. For everyone else, it offers a warning about the limits of generalizability.

Indeed, the geographic concentration of the evidence base is one of the review’s most important caveats. With twenty-six of thirty studies conducted in the United States, the programme theory rests heavily on a healthcare landscape shaped by particular electronic record systems, payment structures, and patient expectations. The authors are explicit that the field needs research in non-USA contexts before the findings can be assumed to travel. They also identify several other gaps: the evidence would benefit from deeper qualitative insight into patient and provider experiences, health economic analysis to establish cost-effectiveness, and longitudinal work exploring equity of outcomes — whether digital signposting narrows disparities or, by favoring the digitally connected, quietly widens them.

What makes this review timely is the scale of the opportunity it describes. Electronic health systems now reach most patients in high-income countries routinely, and every one of those touchpoints is a potential doorway to a preventive intervention that might otherwise never happen. The promise of electronic signposting is not a new drug or a new device but a new delivery architecture for the preventive medicine we already have. The Cambridge team’s programme theory provides the first systematic map of the terrain — the fifty-seven pathways, the patient-side and provider-side levers, the trust dynamics — that determines whether those doorways open. Turning that map into practice will require the field to embrace the review’s central lesson: that the message, the messenger, the medium, and the moment must all align, and that alignment is something that can be designed, tested, and improved.

Subject of Research: Implementation of electronic signposting to cancer prevention interventions through electronic healthcare systems

Article Title: Implementation of electronic signposting to interventions that prevent cancer: A realist review

Article References: Brown, T. J., Tham, N. A. Q., Naughton, F., Goodfellow, H., Hull, L., Jopling, H., Parretti, H. M., Ramsey, A. T., Wagner, A. P., & Khadjesari, Z. (2026). Implementation of electronic signposting to interventions that prevent cancer: A realist review. PLOS Digital Health, 5(10), e0001770. https://doi.org/10.1371/journal.pdig.0001770

Image Credits: AI Generated

DOI: 10.1371/journal.pdig.0001770

Keywords: electronic signposting, cancer prevention, realist review, electronic health records, digital health, health behaviour, implementation science, SMS messaging, patient engagement, health disparities, programme theory, preventive medicine

The original MetaboHealth score was developed as a cost-efficient indicator of overall health, built on high-throughput nuclear magnetic resonance (¹H-NMR) spectroscopy measurements from the Nightingale Health platform. Trained on prospective mortality data from 12 large European cohorts, the score combines 14 metabolic biomarkers—ranging from glucose and albumin to amino acids such as histidine, isoleucine, leucine, phenylalanine, and valine, plus lipoprotein measures—into a weighted sum that captures systemic changes preceding disease. Higher scores on the health-oriented version of the scale indicate better survival prospects, and previous work linked the score to frailty, cognitive decline, COVID-19 outcomes, and loss of functional independence.

But the original score had a practical flaw: it was scaled within individual study populations, meaning two people from different cohorts could not be directly compared. To fix this, the team re-anchored the biomarker distributions using BBMRI-NL, a nationwide Dutch biobank infrastructure encompassing 29,792 participants from 24 cohorts aged 16 to 103. This produced Rescaled-MetaboHealth, a version interpretable at the individual level against a defined population reference. The researchers then went a step further, restricting the score to the 10 biomarkers that have received CE marking as clinically validated components of an in vitro diagnostic device—yielding Personal-MetaboHealth, a score that meets regulatory requirements for real-world clinical use.

The predictive power of the new score was tested in the Leiden Longevity Study, a three-generation cohort of 421 long-lived families. The analysis focused on 2,404 second-generation participants—offspring and their partners—with a mean age of 59.2 years, followed for up to 22 years for mortality and 16 years for disease incidence. During follow-up, 489 participants died and 498 developed morbidity. All three versions of the score performed comparably for all-cause mortality: each standard deviation increase corresponded to a 23 to 25 percent lower risk of death, with hazard ratios of 0.77 for the original score, 0.76 for the rescaled version, and 0.75 for Personal-MetaboHealth.

Where Personal-MetaboHealth truly distinguished itself was in predicting the first onset of cardiometabolic disease, defined using ICD-10 codes for stroke, cerebrovascular accident, angina pectoris, acute myocardial infarction, hypertension, and diabetes. Among the 1,403 participants free of cardiometabolic disease at baseline, each standard deviation increase in Personal-MetaboHealth was associated with a 26 percent lower yearly risk of developing a first cardiometabolic disease—a 12 percent stronger effect than the other two scores. The researchers attribute this advantage partly to the removal of metabolites with higher technical variability, such as acetoacetate and small HDL lipids, which dropped out when the score was confined to the clinically validated subset.

Because the score is known to correlate with lifestyle factors, the team ran robustness checks adjusting for smoking quantity, alcohol consumption, and medication use. The mortality associations weakened slightly but remained significant. For cardiometabolic disease, the original and rescaled scores lost significance entirely after adjustment, largely because of smoking—but Personal-MetaboHealth held firm, with an adjusted hazard ratio of 0.78. This suggests the new score captures broader dimensions of health beyond those affected by smoking, an important property for a tool intended to stratify risk across whole populations.

To translate the statistics into something more intuitive, the researchers applied accelerated failure time models, which express effects in years rather than relative hazards. The result was remarkable: each unit increase in Personal-MetaboHealth corresponded to a 36 percent delay in the onset of first cardiometabolic disease, equivalent to approximately 13.69 additional years before the median participant would be expected to develop their first cardiometabolic condition. The magnitude of this effect is comparable to well-established risk factors such as smoking and socioeconomic status, underscoring just how much information is packed into this single metabolic composite.

Prediction alone, however, is not enough for a screening tool—it must be actionable. To test this, the team turned to the Growing Old Together (GOTO) study, a 13-week single-arm lifestyle intervention involving 164 healthy older adults with a mean age of 62.8 years. Participants achieved a 25 percent reduction in energy balance through a 12.5 percent decrease in caloric intake and a 12.5 percent increase in physical activity, guided by personalized plans from a dietician and physiotherapist aligned with the Dutch Guidelines for a Healthy Diet. Across all participants combined, the intervention produced no significant change in Personal-MetaboHealth. But when the researchers stratified participants by baseline score—using zero on the BBMRI-NL scale as the marker of the average Dutch adult—a clear pattern emerged.

Among the 52 participants whose baseline scores marked them as less healthy than the population average, the intervention produced a significant improvement of 0.26 units, driven by favorable changes in glycoprotein acetyls, glucose, phenylalanine, isoleucine, and leucine—biomarkers reflecting inflammation and metabolic function. These gains were accompanied by improvements in fasting triglyceride, C-reactive protein, and insulin levels. In contrast, the 83 participants who started out healthier showed a slight average decrease of 0.13 units, though 81 percent of them retained a healthy score and they continued to improve in blood pressure, body composition, and fat metabolism, with no significant worsening in any measured parameter—suggesting the dip reflects normal fluctuation within the healthy range rather than harm.

The findings position Personal-MetaboHealth as a candidate for what the authors call an actionable health check in middle age: a blood-based number that identifies who is at risk, quantifies how far ahead disease may lie, and demonstrates that it can be improved through evidence-based lifestyle change. The researchers note that the score captures different aspects of intervention response than epigenetic clocks such as GrimAge, which declined in all GOTO participants and tracked body composition changes, whereas the metabolic score’s improvement in at-risk individuals reflected broader immune-metabolic shifts—implying the two approaches could be complementary. Limitations remain, including the family-based cohort design, baseline-only metabolomic sampling, and a predominantly Caucasian reference population that may not generalize to other ethnic groups. The team plans to validate the score in underrepresented populations and to develop country-specific versions. If those efforts succeed, a routine blood draw in midlife could become the wake-up call that turns years of silent risk into decades of healthier life.

Subject of Research: A metabolomics-based health score for predicting mortality and cardiometabolic disease and its response to lifestyle intervention

Article Title: Personal-MetaboHealth, an actionable health check in middle age, is improved by an effective lifestyle intervention in those at risk

Article References: van den Berg, N., Natalle Lopes, G., Bogaards, F. A., Beekman, M., Amaro Junior, E., Slagboom, P. E., & Deelen, J. (2026). Personal-MetaboHealth, an actionable health check in middle age, is improved by an effective lifestyle intervention in those at risk. BMC Medicine, 24(1), Article 470. https://doi.org/10.1186/s12916-026-05178-z

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05178-z

Keywords: Personal-MetaboHealth, metabolomics, biomarkers, cardiometabolic disease, all-cause mortality, lifestyle intervention, biological aging, NMR spectroscopy, preventive medicine, Leiden Longevity Study, healthy lifespan, risk stratification

The scale of the challenge becomes clear when one considers what whole-genome sequencing actually involves. Reading a person’s genetic information means capturing roughly 40,000 genes together with the vast regulatory regions that control their function. Dr. Gyula Richárd Nagy, a clinical geneticist and associate professor in the Department of Obstetrics and Gynecology at Semmelweis University, offers a vivid illustration of the volume: if all of this genetic text were laid out side by side, it would fill approximately 4,000 books of 500 pages each. The international Human Genome Project, launched in 1990 to map this enormous text, produced its first draft in 2001, but it was not until 2022 that researchers finally assembled a substantially complete, gap-free human genome. Even now, every new genome sequenced in a clinic or research laboratory must be interpreted by comparing it against a reference, and that comparison is performed almost entirely by automated software processing massive quantities of data.

The reference sequence currently in use worldwide is known as GRCh38. It represents the standard coordinate system against which variations in any individual’s genetic makeup are assessed. The problem, as the Semmelweis researchers point out, is that GRCh38 is not an average human genome that applies equally to everyone. It is built on a single, linear reference coordinate system, and although it incorporates genetic data from multiple individuals, roughly seventy percent of its content derives from the genome of a single male donor from Buffalo in the United States. When the software encounters a healthy genetic variant in a patient that happens to be listed in the reference as an exceptionally rare minor allele, it may trigger a false alarm. In other words, if the map fails to capture the true breadth of human genetic diversity, healthy traits can easily be mistaken for defects, particularly when the interpretation is left solely to automated pipelines without expert oversight.

The Hungarian study demonstrated exactly how this vulnerability plays out in practice. The whole genomes of twenty healthy volunteers were aligned against GRCh38, and in all twenty cases the automated analysis identified the same severe genetic variant. Only after expert curation, which cross-checked the findings against additional representative population regions, was the variant shown to be erroneous. None of the twenty individuals carried a medically relevant variant at all. Dr. Balázs Győrffy, Head of the Department of Bioinformatics at Semmelweis University and co-lead author of the paper, describes the result as the demonstration of an important bioinformatics vulnerability, one that arises not from faulty sequencing technology but from the inadequacy of the reference against which the sequences are judged.

At present, this weakness does not translate into clinical harm, because the discrepancies flagged by software are routinely reviewed and analyzed manually by specialists who consult other population databases before any conclusion is drawn. Human expertise acts as a safety net, catching the false positives that the automated systems generate. However, that safety net has a cost. Dr. Nagy warns that if whole-genome screening were expanded to large populations, the volume of manual corrections required would create an unsustainable bottleneck. Each false alarm demands expert time, and multiplying those demands across millions of screened individuals could overwhelm the very workforce needed to deliver the promised benefits of preventive genomics. In this sense, the reference genome problem is not merely a technical curiosity but a potential obstacle to the future expansion of population-wide preventive screening.

The solution proposed by the researchers is a graph-based pan-genome, a fundamentally different way of representing human genetic variation. Instead of describing the DNA sequence of a single person as one linear string, a pan-genome graph depicts the common and divergent segments of many human genomes in a branching, network-like structure. Such a computational reference already exists, and it offers a much richer genetic mapping system that covers human diversity more comprehensively. Crucially, it would eliminate the class of errors observed in the Hungarian study by design, because a variant common in some populations would appear in the graph as a known branch rather than as an alarming rarity. Comparing every person’s genome to a diverse network of genomes, rather than to a single reference sequence, provides a far more accurate picture of what is genuinely rare and what is simply part of normal human variation.

Yet the existence of a pan-genome graph does not mean it is ready for routine clinical use. Dr. Győrffy identifies the key question for the future as the extent to which information technology will be able to keep pace with advances in medicine. Current everyday IT systems, he notes, simply cannot support the daily use of such massive databases. Graph genomes are computationally far more demanding than linear references, requiring more storage, more processing power and more sophisticated alignment algorithms. Bridging the gap between a working computational prototype and a system that hospitals and screening programs can rely on every day is a formidable engineering challenge, and one that the researchers argue must be tackled proactively rather than reactively.

Dr. Nagy emphasizes that actively exploring the limits of the technology is essential if this branch of preventive medicine is to provide the highest level of safety without compromises. Genetic testing is already embedded in modern medicine in more targeted forms. For certain cancers, tumor samples are analyzed to identify genetic abnormalities that indicate which targeted therapy is likely to be effective. Genetic testing also plays an important role in diagnosing and treating rare conditions, in detecting hereditary diseases, and in assessing risk among affected family members, enabling early detection and preventive interventions in fields such as cardiogenetics. These applications demonstrate the clinical value of reading genetic information, but they operate on a far smaller scale than the whole-population vision that whole-genome sequencing promises.

The fundamental approach of future preventive and predictive medicine goes beyond treating disease once it has developed. The researchers argue that its core premise is knowing the risk before symptoms appear, and knowing who needs timely attention and for what. Whole-genome sequencing could give every person a personalized guide to their disease risks and predispositions, opening the door to genuinely individualized prevention strategies. That future, however, depends on a reference map worthy of the name. Until a graph-based pan-genome can be deployed routinely, and until the IT infrastructure catches up with the medical ambition, every automated genome analysis will carry the risk of mistaking healthy human diversity for disease, a risk that only expert human judgment currently stands between. The study, published in GeroScience under DOI 10.1007/s11357-026-02436-z, is a timely reminder that the tools we use to read the book of life must be as sophisticated as the book itself.

Subject of Research: Limitations of the GRCh38 human reference genome in automated whole-genome sequencing and the case for a graph-based pan-genome

Article Title: We may need a new map to properly interpret our genome

Article References: We may need a new map to properly interpret our genome. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: whole-genome sequencing, reference genome, GRCh38, pan-genome, bioinformatics, preventive medicine, genetic variants, false positives, personalized medicine, GeroScience, Semmelweis University, genomic screening